{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:08:16Z","timestamp":1781510896394,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.radonc.2019.07.028","type":"journal-article","created":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T16:37:24Z","timestamp":1566059844000},"page":"66-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Safety and efficacy of reduced dose and margins to involved lymph node metastases in locally advanced NSCLC patients"],"prefix":"10.1016","volume":"143","author":[{"given":"Judi N.A.","family":"van Diessen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margriet","family":"Kwint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5155-5274","authenticated-orcid":false,"given":"Jan-Jakob","family":"Sonke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Walraven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Stam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianus J.","family":"de Langen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Knegjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 S.A.","family":"Belderbos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2019.07.028_b0005","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2019.07.028_b0010","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/j.ijrobp.2017.06.250","article-title":"Long-term results of RTOG 0617: a randomized phase 3 comparison of standard dose versus high dose conformal chemoradiation therapy +\/- Cetuximab for Stage III NSCLC","volume":"99","author":"Bradley","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2019.07.028_b0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cllc.2014.08.002","article-title":"Radical-intent hypofractionated radiotherapy for locally advanced non-small-cell lung cancer: a systematic review of the literature","volume":"16","author":"Kaster","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2019.07.028_b0020","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cllc.2013.03.002","article-title":"Toxicity of concurrent radiochemotherapy for locally advanced non\u2013small-cell lung cancer: a systematic review of the literature","volume":"14","author":"Koning","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2019.07.028_b0025","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/j.ijrobp.2009.05.070","article-title":"Radiation dose-volume effects in the esophagus","volume":"76","author":"Werner-Wasik","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2019.07.028_b0030","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.ijrobp.2009.06.091","article-title":"Radiation dose-volume effects in the lung","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2019.07.028_b0035","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.radonc.2016.04.025","article-title":"Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation","volume":"119","author":"Tucker","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2019.07.028_b0040","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1016\/j.ijrobp.2012.03.027","article-title":"Acute esophagus toxicity in lung cancer patients after intensity modulated radiation therapy and concurrent chemotherapy","volume":"84","author":"Kwint","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2019.07.028_b0045","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ijrobp.2013.07.029","article-title":"Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis","volume":"87","author":"Palma","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2019.07.028_b0050","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.radonc.2017.09.004","article-title":"Heart dose associated with overall survival in locally advanced NSCLC patients treated with hypofractionated chemoradiotherapy","volume":"125","author":"Stam","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2019.07.028_b0055","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.radonc.2017.08.008","article-title":"Brainstem dose is associated with patient-reported acute fatigue in head and neck cancer radiation therapy","volume":"126","author":"Ferris","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2019.07.028_b0060","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.radonc.2016.02.008","article-title":"Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy","volume":"118","author":"van Diessen","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2019.07.028_b0065","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3109\/0284186X.2013.868035","article-title":"Pattern of loco-regional failure after definitive radiotherapy for non-small cell lung cancer","volume":"53","author":"Schytte","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2019.07.028_b0070","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.radonc.2017.11.002","article-title":"Patterns of locoregional failure in locally advanced non-small cell lung cancer treated with definitive conformal radiotherapy: results from the Gating 2006 trial","volume":"126","author":"Jouglar","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2019.07.028_b0075","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.ijrobp.2014.07.038","article-title":"Differential motion between mediastinal lymph nodes and primary tumor in radically irradiated lung cancer patients","volume":"90","author":"Schaake","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2019.07.028_b0080","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1007\/s00259-008-0874-2","article-title":"The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials","volume":"35","author":"Boellaard","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2019.07.028_b0085","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.ijrobp.2006.04.031","article-title":"Mid-ventilation CT scan construction from four-dimensional respiration-correlated CT scans for radiotherapy planning of lung cancer patients","volume":"65","author":"Wolthaus","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2019.07.028_b0090","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0360-3016(01)02805-X","article-title":"Inclusion of geometric uncertainties in treatment plan evaluation","volume":"52","author":"van Herk","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2019.07.028_b0095","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.radonc.2014.10.009","article-title":"Intra thoracic anatomical changes in lung cancer patients during the course of radiotherapy","volume":"113","author":"Kwint","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2019.07.028_b0100","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/oxfordjournals.aje.a116813","article-title":"Simulation study of confounder-selection strategies","volume":"138","author":"Maldonado","year":"1993","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.radonc.2019.07.028_b0105","first-page":"CD002140","article-title":"Concurrent chemoradiotherapy in non-small cell lung cancer","author":"O'Rourke","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.radonc.2019.07.028_b0110","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.lungcan.2018.06.020","article-title":"Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: results from a prematurely terminated randomized phase II trial","volume":"122","author":"Hallqvist","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2019.07.028_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174268","article-title":"Lymph node volume predicts survival but not nodal clearance in Stage IIIA-IIIB NSCLC","volume":"12","author":"Agrawal","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.radonc.2019.07.028_b0120","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.radonc.2016.02.011","article-title":"Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab","volume":"118","author":"Walraven","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2019.07.028_b0125","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2006.09.005","article-title":"Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972\u201322973)","volume":"43","author":"Belderbos","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2019.07.028_b0130","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.cllc.2013.04.001","article-title":"Prediction of acute toxicity grade >\/= 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin","volume":"14","author":"Uyterlinde","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2019.07.028_b0135","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.radonc.2013.08.017","article-title":"Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy","volume":"108","author":"Chen","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2019.07.028_b0140","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ijrobp.2018.07.188","article-title":"Concurrent daily cisplatin and high-dose radiation therapy in patients with stage III non-small cell lung cancer","volume":"102","author":"Dieleman","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781401933021X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781401933021X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:09:23Z","timestamp":1759122563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016781401933021X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":28,"alternative-id":["S016781401933021X"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2019.07.028","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of reduced dose and margins to involved lymph node metastases in locally advanced NSCLC patients","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2019.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}